Resource Hub

NAMs and the Next Inflection Point for Imaging Manufacturers

For decades, diagnostic imaging manufacturers have anchored their growth strategies to clinical demand, capital cycles, and incremental modality innovation. However, a quieter (and potentially more disruptive) shift is now underway upstream in the life sciences.…

March 26, 2026

|SMG Admin

NAMs, NIH Policy, and What it Means for Diagnostics

The NIH’s growing emphasis on New Approach Methodologies (NAMs) marks a significant change in how biomedical research, particularly drug development, is being conducted. Prompted by legislative changes, evolving regulatory guidance, and long-standing concerns about the…

March 20, 2026

|Daniel Granderson